The use of micro-costing in economic analyses of surgical interventions:A systematic review by Potter, Shelley et al.
                          Potter, S., Davies, C., Davies, G., Rice, C., & Hollingworth, W. (2020).
The use of micro-costing in economic analyses of surgical
interventions: A systematic review. Health Economics Review, 10, [3
(2020)]. https://doi.org/10.1186/s13561-020-0260-8
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1186/s13561-020-0260-8
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via BMC at
https://healtheconomicsreview.biomedcentral.com/articles/10.1186/s13561-020-0260-8 . Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/user-guides/explore-bristol-research/ebr-terms/
REVIEW Open Access
The use of micro-costing in economic
analyses of surgical interventions: a
systematic review
Shelley Potter1,2†, Charlotte Davies1*† , Gareth Davies1, Caoimhe Rice3 and William Hollingworth3
Abstract
Background: Compared with conventional top down costing, micro-costing may provide a more accurate method
of resource-use assessment in economic analyses of surgical interventions, but little is known about its current use.
The aim of this study was to systematically-review the use of micro-costing in surgery.
Methods: Comprehensive searches identified complete papers, published in English reporting micro-costing of
surgical interventions up to and including 22nd June 2018. Studies were critically appraised using a modified
version of the Consensus on Health Economic Criteria (CHEC) Checklist. Study demographics and details of
resources identified; methods for measuring and valuing identified resources and any cost-drivers identified in each
study were summarised.
Results: A total of 85 papers were identified. Included studies were mainly observational comparative studies
(n = 42, 49.4%) with few conducted in the context of a randomised trial (n = 5, 5.9%). The majority of studies
were single-centre (n = 66, 77.6%) and almost half (n = 40, 47.1%) collected data retrospectively. Only half
(n = 46, 54.1%) self-identified as being ‘micro-costing’ studies. Rationale for the use of micro-costing was most
commonly to compare procedures/techniques/processes but over a third were conducted specifically to
accurately assess costs and/or identify cost-drivers. The most commonly included resources were personnel
costs (n = 76, 89.4%); materials/disposables (n = 76, 89.4%) and operating-room costs (n = 62,72.9%). No single
resource was included in all studies. Most studies (n = 72, 84.7%) identified key cost-drivers for their
interventions.
Conclusions: There is lack of consistency regarding the current use of micro-costing in surgery. Standardising
terminology and focusing on identifying and accurately costing key cost-drivers may improve the quality and
value of micro-costing in future studies.
Trial registration: PROSPERO registration CRD42018099604.
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Background
Accurate information regarding the cost-effectiveness
of existing and novel surgical interventions is vital to
inform policy and ensure scarce resources are used to
optimal benefit. Central to the meaningful assessment
of cost-effectiveness is the accurate evaluation of re-
source use [1]. This is commonly undertaken using a
‘top-down’ or ‘gross-costing’ approach whereby aver-
age costs are used to estimate resource use. For in-
stance, in England, national reference costs based on
healthcare resource groups (HRGs) can be used to es-
timate the average cost per inpatient episode for
groups of surgical procedures (e.g. “very major hip
procedures for non-trauma”) [2]. While this method
is straightforward, it is too crude for many purposes.
For example, it is not possible to compare the costs
of two different surgical procedures within the same
procedure group (e.g. cemented vs hybrid total hip
replacements) or evaluate a modification to an exist-
ing procedure when the procedure itself is unchanged
(e.g. single port vs standard multiple port laparoscopic
appendicectomy). Furthermore, gross costing ap-
proaches may not be suitable for evaluating novel
surgical interventions (e.g. robotic cardiac surgery)
which do not fall within existing HRGs. Micro-
costing is a method that allows for more precise
assessment of the economic costs of a healthcare
intervention [3]. Defined as the ‘direct enumeration
and costing of every input consumed in the treatment
of a particular patient’ [4], micro-costing attempts to
measure costs of a service as accurately as possible. The
process has three stages; the identification of all resources
involved in the provision of care (e.g. human-resources/
theatre-time/consumables); accurate measurement of each
resource (for example using time-and-motion studies);
and valuation of the resources used. Although this ap-
proach is time-consuming, it may more accurately reflect
the cost of surgical procedures, especially if the procedure
is new or includes the use of expensive implants or
consumables. It may therefore be the most appropriate
method of resource use assessment alongside surgical
trials.
The potential value of this methodology has already
been identified and a framework has been developed for
applying micro-costing methodology to cost evaluations
of surgical technologies [5]. This framework focuses spe-
cifically on direct costs which reflect the price of re-
sources directly attributable to the procedure rather
than indirect costs (e.g. overheads) which have to be es-
timated using an allocation formula [5]. The framework
divides the direct costs into two categories; fixed costs
which do not vary according to the level of activity (e.g.
personnel costs and medical devices e.g. robotic systems)
and variable costs such as reusable instruments and
disposables which vary according to the type or number
of procedures performed. A recent review of use of
micro-costing in bariatric surgery suggests that this
framework may be more widely applicable to surgical in-
terventions [6], but further work is required to deter-
mine whether it is generalisable to a range of surgical
procedures.
Despite the potential benefits of micro-costing, it is
time and resource intensive and this may limit its utility
in clinical trials. Work is therefore needed to explore
whether a more targeted approach may be possible. It is
hypothesised that surgical interventions will have ‘cost-
drivers’ which create or drive the majority of the cost of
the activity. If these are consistent across surgical inter-
ventions or can be easily identified, it may be possible to
develop a simplified micro-costing framework which
could be used in future surgical trials.
The aim of this systematic review was therefore to
identify and critically appraise published studies
reporting the use of micro-costing in economic
analyses of surgical interventions to explore the re-
sources included in each study; the methods used for
measuring and valuing resource use and reported
cost-drivers of surgical interventions to inform recom-
mendations for the future use of micro-costing in
surgical interventions.
Methods
The protocol for this systematic review was registered on
the PROSPERO International prospective register of sys-
tematic reviews (reference number CRD42018099604) be-
fore data extraction commenced.
Literature search strategy
The OVID SP versions of MEDLINE, Embase, EconLit,
the Cochrane Database and the NHS Economic Evalu-
ation Database (NHS EED) were searched using published
micro-costing search strategies [6–8] and appropriate
search terms for ‘surgery’ developed in collaboration with
an information specialist (Additional file 1). The combined
search strategy was tested iteratively to ensure the sensi-
tivity in identifying micro-costing studies known to the
authors.
The search was limited to human studies, published in
English from database inception up to and including 22nd
June 2018. Abstracts and conference reports were ex-
cluded due to difficulty assessing incomplete information.
Duplicate records were excluded, and titles and ab-
stracts of remaining citations were screened for eligibil-
ity using prespecified inclusion criteria (see below). The
reference lists of identified studies and existing reviews
were also manually searched to identify any additional
relevant papers.
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Selection of papers
Full papers reporting the use of micro-costing as a
method of resource-use assessment in economic ana-
lyses of surgical interventions were eligible for inclusion.
For the purposes of the review, a surgical intervention
was defined as any ‘procedure involving an incision with
instruments usually performed in an operating theatre
and normally involving anesthesia and/or respiratory as-
sistance’ [9]. Micro-costing was defined as the ‘direct
enumeration and costing of every input consumed in the
treatment of a particular patient’ [4]. Initial scoping
demonstrated that many studies stated having under-
taken a micro-costing exercise but did not report any
details of the resources included or how these resources
had been measured or valued. Such studies were not
considered informative so only those considered to rep-
resent a ‘sufficiently-detailed micro-costing exercise’
were eligible for inclusion.
The definition of a ‘sufficiently detailed’ micro-costing
study was iteratively modified during the pilot abstract
screening and data extraction phase which included ap-
proximately 100 abstracts and 10 papers respectively.
The piloting and iterative modification of the abstract
screening and data extraction pro-formas were com-
pleted by 2 reviewers (CD/SP) following discussion with
experienced health economists (WH/CR). For the
purposes of this review, a ‘sufficiently-detailed micro-
costing study’ was agreed to be one in which i) the
elements of the surgical procedure were sufficiently
disaggregated and at the very least two separate elements
of the procedure (e.g surgeon costs and consumables)
costs presented separately AND ii) the unit cost of at
least one element of the procedure (e.g. cost per minute
of surgeon time; cost per implant) had been considered.
Any studies not meeting both of these criteria were
excluded.
Economic analyses using ‘top down’ or gross-costing
approaches (e.g. HRGs), economic models, conceptual
papers, reviews, commentaries, letters, abstracts, edito-
rials and studies not evaluating surgery were excluded.
Studies comparing surgery with a non-surgical compara-
tor were included provided that micro-costing of the
surgical intervention had been performed and met the
inclusion criteria.
All papers were screened for inclusion by two re-
viewers (CD and SP/GD) using a standardised two-stage
screening proforma (Additional file 2). Phase 1 (abstract
screening) focused on identifying original full papers
reporting economic analyses of surgical interventions
using a micro-costing approach. Papers meeting these
inclusion criteria or in which there was uncertainty pro-
ceeded to phase 2 (full-text screening). Only papers
meeting all the inclusion criteria following full-text
screening were included in the review. Uncertainties that
remained after full-text review were resolved by discus-
sion with an experienced health economist (CR/WH).
Reasons for exclusion were recorded.
Data extraction
Data were extracted using a standardised REDCap [10]
data extraction proforma and included three sections; i)
study and surgical procedure characteristics, ii) critical
appraisal and iii) details of the micro-costing method-
ology reported (Additional file 3).
Study and surgical procedure characteristics
Study details included year of publication and country of
origin; study design (randomised controlled trial or ob-
servational study with or without comparison group);
prospective or retrospective accrual of data; author-
reported type of economic analysis undertaken (e.g.
micro-costing; cost analysis, cost-effectiveness analysis;
economic analysis; other, irrespective of whether this
was considered appropriate); number of participating
centres (in the micro-costing study separately); surgical
specialty with details of the intervention(s) assessed;
whether implants were used (yes or no); type of hospital
stay (day-case; inpatient, both or not stated); type of an-
aesthetic (general, local, both or not stated); details of
the study population and stated aims and objectives of
the study which were extracted verbatim.
Critical appraisal
In the absence of a specific quality assessment tool for
micro-costing studies, a modified version of the Consen-
sus on Health Economic Criteria (CHEC) Checklist [11]
was used to assess the quality of included studies. The
CHEC checklist represents a generic core set of 19 items
that can be used to assess the methodological quality of
economic evaluations. As this review focuses specifically
on the use of micro-costing in economic analyses of sur-
gical interventions, items relating to the appropriateness
of the selected time horizon (item 5); the quality of out-
come assessment (items 10–12) and the appropriate dis-
counting of future costs and outcomes (item 14) were
not considered relevant and were not assessed.
Items 7–9 which assess the degree to which all rele-
vant costs were appropriately identified, measured and
valued were the focus of the review and were expanded
to include additional details (see below).
Reporting of micro-costing methodology
Details of the micro-costing undertaken in each included
study were extracted. This included assessing whether
the authors reported performing a ‘micro-costing’ study
or if alternative terms were used; the purpose of the
study (e.g. to compare surgical procedure costs or to
compare costing methodologies); methods of resource
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identification (e.g. patient pathway mapping, interviews
with medical staff,) and the scope of the costing exercise
(e.g. pre-operative planning; surgical procedure; post-
operative hospital stay).
Resources included in each micro-costing study
were recorded (yes/no) using the categories proposed
in the existing framework [5] expanded based on ini-
tial scoping work and expertise within the study team.
These included costs relating to personnel; materials/
disposables; medical devices; reusable instruments; the
operating room; inpatient hospital stay; overhead/ad-
ministration; drugs/medications; investigations/im-
aging; complications; follow-up and other costs. For
each resource category, specific details of what
resources were included (e.g. surgeon, nursing and
anaesthetist time in ‘personnel costs’); and details of
how these resources were i) measured (e.g. interviews;
time and motion studies) and ii) valued (e.g. invoice
amounts; hospital human resources departments; pro-
vider price catalogues) were extracted verbatim. Fi-
nally, we recorded any cost drivers identified by the
authors (yes/no) with verbatim details of cost-drivers
reported. Most studies did not report results in suffi-
cient detail for us to apply a quantitative definition to
identify ‘cost drivers’ or compare their relative im-
portance between studies. Therefore, we are limited
to providing a narrative summary of author-identified
cost drivers. Similarly, there was insufficient detail to
determine whether the reported studies distinguished
adequately between static cost drivers, accounting for
the highest proportion of total cost at a given point
in time, and dynamic cost drivers, making the main
contribution to the growth of total costs over time.
Data extraction was performed by one reviewer
(CD) with a proportion (10%) checked by a second
reviewer (SP/GD). Discrepancies were resolved by
discussion with an experienced health economist (CR/
WH).
Analysis
Descriptive statistics were used to summarise study de-
tails; compliance with items in the CHEC checklist and
details of the micro-costing reported in each study. Sim-
ple content analysis [12] was used to categorise verbatim
data relating to study aims and objectives; methods used
for identifying, measuring and valuing resources and de-
tails of any reported cost-drivers. Stata/MP 15 was used
for all quantitative analyses.
Results
Study selection
Of the 1009 abstracts identified from the electronic
searches, 243 full papers were obtained for further evalu-
ation. Of these, 79 met the inclusion criteria and were
retained. A further six papers were identified from the
hand-search. A total of 85 papers were therefore in-
cluded in the review (Fig. 1). Included papers are listed
in Additional file 4.
Study and procedure characteristics
The characteristics of the included studies are sum-
marised in Table 1. Studies were most frequently pub-
lished between 2016 and 2018 (n = 34, 40.0%) and the
majority originated from Europe (n = 41, 48.2%) or
North America (n = 21, 24.7%). Included studies were
commonly single-centre (n = 66, 77.6%), retrospective
(n = 40, 47.1%), observational studies with (n = 46,
54.1%) or without (n = 21, 24.7%) a comparison group.
Authors’ most frequently described their studies as being
‘cost analyses’ (n = 54, 63.5%) and the median number of
procedures micro-costed per study was 100 (interquar-
tile range 24–233) although this ranged widely (Table 1).
Orthopaedic (n = 22, 25.9%), general (n = 14, 16.5%)
and plastic surgical (n = 9, 10.6%) procedures were
micro-costed most frequently but a comprehensive
range of surgical specialities were represented and al-
most a third of studies micro-costed a surgical proced-
ure involving an implant (n = 25, 29.4%). Most
procedures were performed under general anesthesia
(n = 39, 46.4%) and required an inpatient hospital stay
(n = 43, 50.6%) but this information was often not clearly
reported (Table 1).
Critical appraisal
The majority of studies scored highly according to the
CHEC checklist (Table 2). Included studies largely had a
well-designed research question (n = 85, 100%) in a
clearly defined population (n = 84, 98.8%) and were using
an appropriate economic study design to achieve their
stated objectives (n = 85, 100%). The study perspective
was less well-reported (n = 49, 57.6%) and only a quarter
of studies (n = 23, 27.1%) performed any form of sensi-
tivity analysis. Most studies discussed the generalisability
of the results to other settings and patient/client groups
(n = 76, 89.4%). A quarter of studies (n = 21, 24.7%) did
not report any conflicts of interest; only half (n = 43,
50.6%) reported obtaining ethical approval for the
project.
Reporting of micro-costing methodology
Table 3 summarises details of the micro-costing under-
taken in the included studies. There was a lack of
consistency regarding study terminology with just over
half of authors (n = 46, 54.1%) describing their method-
ology as ‘micro-costing’ while a third (n = 27/85, 31.8%)
used the term (time-driven) activity-based costing (ABC)
and a smaller number referred to using a ‘bottom-up’
approach (n = 4/85, 4.7%).
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Micro-costing was most commonly performed to com-
pare procedures, techniques or processes (n = 43, 50.6%)
but over a third of studies (n = 29, 34.1%) were specific-
ally undertaken to identify cost-drivers for surgical pro-
cedures and a quarter (n = 20, 23.5%) were performed to
compare costing methodologies; most commonly gross
or ‘top-down’ methods, such as HRGs or insurance re-
imbursement with micro-costing or ‘bottom-up’ ap-
proaches. In addition to micro-costing the actual
surgical procedure, most studies (n = 72, 84.7%) also
micro-costed the patients’ hospital stay. Pre-operative in-
vestigations required prior to surgery were included in
over half the studies (n = 48, 56.5%) and a third micro-
costed surgical complications (n = 29, 34.1%) and/or
follow-up required after discharge (n = 29, 34.1%). Most
studies reported including either direct costs only (n =
24, 28.2%) or both direct and indirect costs (n = 29,
34.1%) but over a third (n = 32, 37.6%) did not state what
types of costs had been considered.
Although most studies included personnel costs (n =
76, 89.4%); materials and disposables (n = 76, 89.4%); op-
erating room costs (n = 62, 72.9%) and/or the costs of
any drugs or medications (n = 63, 74.1%) in their micro-
costing, there was no single type of resource included in
all studies and categorisation of resources into pre-
defined categories was often difficult due to different
studies aggregating and reporting resources in different
ways. There was also a lack of consistency in the ways in
which relevant resources were identified, measured and
valued. Hospital information systems or administrative
databases were used in over 40% (n = 37, 43.5%) of
studies with approximately a third (n = 32, 37.6%) using
patient pathway mapping to identify resource-use. Inter-
views with surgeons and/or patients (n = 26, 30.5%) and
direct observation (n = 20, 23.5%) were less commonly
used (Table 3).
Identification of cost-drivers
The majority of included studies (n = 72, 84.7%) reported
having identified cost-drivers but these differed accord-
ing to whether the authors had micro-costed the surgical
procedure alone or the whole episode of care (surgical
procedure including the inpatient stay +/− preoperative
investigations +/− follow-up) (Table 4). For studies just
considering the surgical procedure, the main cost-
drivers were identified as the costs of the operating the-
atre (n = 17, 28.3%); theatre personnel (n = 15, 25.0%);
operative equipment (n = 9, 15.0%), implants (n = 7,
Fig. 1 PRISMA diagram for the systematic review
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11.7%) and theatre consumables (n = 6, 10.0%). For stud-
ies micro-costing the full episode of care, the main cost-
drivers identified were the inpatient stay (n = 25, 35.7%)
and personnel/labour costs (n = 14, 20%). Use of inten-
sive care (n = 7, 10%); consumables (n = 6, 8.6%) and
overheads (n = 6, 8.6%) were also identified as potential
cost-drivers in these studies (Table 4).
Discussion
Micro-costing may offer a more accurate method for
costing in economic analyses of surgical interventions,
but this review suggests that current use of the method-
ology is inconsistent and, in many instances, lacking in
methodological rigor. There is a lack of consistency re-
garding terminology used; the types of resources in-
cluded and the methods by which these are measured
and valued. Almost half of studies used retrospectively
collected data (e.g. from hospital administrative or infor-
mation systems). Although routinely available data
sources may be accurate, especially in modern ‘fee-for-
service’ settings, other reported methods for resource
use identification such as case-note review or operating
room logs may be less robust [13–15], potentially com-
promising the validity of the micro-costing approach.
Over three quarters of all studies were undertaken at a
single centre limiting the generalizability of the results.
Almost half of the included studies did not report re-
source utilization and unit cost data separately. Instead
summary costs were presented with limited disaggrega-
tion of individual costs or transparency regarding
Table 1 Study and surgical procedure characteristics (n = 85)
n (%)
Year of publication
Pre 2000 4 (4.7)
2001–2005 5 (5.9)
2006–2010 11 (12.9)
2011–2015 31 (36.5)
2016–2018 34 (40.0)
Study design
Within/as part of RCT 5 (5.9)
Observational comparative study 42 (49.4)
Case/control study 4 (4.7)
Case-series 21 (24.7)
Other 13 (15.3)
Data collection
Prospective 27 (31.8)
Retrospective 40 (47.1)
Combination of prospective and retrospective 4 (4.7)
Not clear/not stated 14 (16.5)
Type of economic analysis reported by study authors
Cost analysis 54 (63.5)
Micro-costing/activity-based costing 13 (15.3)
Cost-effectiveness analysis 6 (7.1)
Economic analysis 4 (4.7)
Cost Consequence Analysis 3 (3.5)
Cost-utility analysis 1 (1.2)
Other 4 (4.7)
Country of origin
Europe 41 (48.2)
USA 21 (24.7)
UK 7 (8.2)
Canada 4 (4.7)
Other 6 (7.1)
Multinational 6 (7.1)
Number of participating centres
Single centre 66 (77.6)
Multicentre 16 (18.8)
Not clear/not stated 3 (3.5)
Number of patients/procedures
micro-costed (median, interquartile
range, range)
100 (24–233) (6–2130)
Surgical speciality
Orthopaedics 22 (25.9)
General surgery 14 (16.5)
Plastic surgery 9 (10.6)
Obstetrics and gynaecology 8 (9.4)
ENT 7 (8.2)
Table 1 Study and surgical procedure characteristics (n = 85)
(Continued)
n (%)
Maxillofacial surgery 5 (5.9)
Cardiothoracic surgery 5 (5.9)
Urology 3 (3.5)
Neurosurgery 2 (2.4)
Vascular surgery 1 (1.2)
Other 4 (4.7)
Surgical procedure involving an implant 25 (29.4)
Type of anaesthesia used
General anaesthesia only 39 (46.4)
Local anaesthesia only 4 (4.8)
Both local and general anaesthesia 5 (6.0)
Not stated/not clear 36 (42.9)
Type of hospital stay
Day-case procedures 13 (15.3)
Inpatient procedures 43 (50.6)
Both day-case and inpatient procedures 11 (12.9)
Not stated/not clear 18 (21.2)
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precisely which resources had been included making
meaningful interpretation difficult. Some good examples of
micro-costing surgical interventions, however, were identi-
fied [16, 17] and have subsequently been published [18].
There was significant variation in which aspects of the
patient pathway researchers elected to micro-cost. Most
studies costed both the surgical procedure and the asso-
ciated inpatient stay, but others also included pre-
operative planning/investigations, complications and
follow-up required following discharge. To an extent,
this variation may appropriately reflect the diversity in
the aims of micro-costing studies. For economic evalua-
tions comparing two different surgical interventions re-
searchers may legitimately focus on the incremental cost
differences between the two procedures and exclude
costs that are common to both procedures (e.g. pre-
operative visits). Furthermore, for economic evaluation,
methodological guidelines emphasise that the level of re-
source use detail required is lower for items with a small
relative impact on total costs (e.g. volatile anaesthetic
agents) [19]. In contrast, for studies aiming to compare
the actual costs of surgery to “top down” costs (e.g. hos-
pital reimbursement), it is important to include all ele-
ments contributing to cost. The level of detail may also
be constrained by study setting and in particular the
granularity of the unit costs available for valuing re-
sources. Studies in settings with itemised fee for service
hospital reimbursement have greater scope to cost re-
source use in much finer detail. Approximately one in
four studies compared a measured cost of performing a
procedure, as determined by micro-costing, with proced-
ure reimbursement rates, which were often considered
to be insufficient. Many of these studies were under-
taken by clinicians. The scope of micro-costing (e.g. pro-
cedure based or full admission) and the economic
perspective (hospital or wider health service) in such
studies should be rigorously appraised to ensure it is not
biased by clinicians’ financial interests. Cost-drivers were
identified and reported in most studies, but these dif-
fered according to which aspects of the patient pathway
were included. There is a need for a standardized defin-
ition of a cost driver in the literature so that authors are
consistent with this terminology and how it is measured
and reported. Although, it was clear from the reported
studies in this review that the cost drivers were the re-
sources that involved the highest proportion of the total
costs of the surgical pathway and/or surgical procedure,
this proportion may in some studies have been below
50% of total cost and/or may have subsumed several cost
drivers instead of only one cost driver per pathway or
procedure.
This review has demonstrated the need for specific
guidance for researchers undertaking micro-costing.
Work to develop a checklist for the conduct, reporting
and appraisal of micro-costing studies in healthcare is
ongoing [20]. This checklist may improve the quality of
future studies but is not specific to surgery which pre-
sents unique challenges. A framework for costing surgi-
cal technologies [5] provides formulae for estimating the
fixed (device and personnel) and variable (re-usable
equipment and disposables) costs of surgery. However,
the framework only considers the costs of the operative
procedure which limits its applicability for trials of surgi-
cal procedures likely to have resource-use implications
beyond the operating theatre such as differential length
of inpatient stay; use of intensive care or need for
follow-up investigations. The framework also excludes
indirect costs (overheads) of surgery which are necessary
Table 2 Quality assessment of included studies
n (%)
Is the study population clearly defined?
Yes 84 (98.8)
No 1 (1.2)
Are the competing alternatives clearly described?
Yes 63 (74.1)
Not applicable 22 (25.9)
Is a well-designed research question posed in an answerable form?
Yes 85 (100.0)
Is the economic study design appropriate to the stated objective?
Yes 85 (100)
Is the actual perspective chosen appropriate?
Yes 48 (56.5)
No 1 (1.2)
Not stated 36 (42.4)
Sensitivity analysis performed
No sensitivity analysis performed 61 (71.8)
Deterministic sensitivity analysis 18 (21.2)
Stochastic sensitivity analysis 2 (2.4)
Other stated sensitivity analysis 3 (3.5)
Not stated/not clear 1 (1.2)
Do the conclusions follow from the data reported?
Yes 85 (100)
Does the study discuss the generalizability of the results to other
settings and patient/client groups?
Yes 76 (89.4)
No 9 (10.6)
Do the authors reports any conflict of interest?
Yes 7 (8.2)
No 57 (67.1)
Not stated 21 (24.7)
Was ethical approval obtained for the study?
Yes 43 (50.6)
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for micro-costing analyses wishing to compare surgical
care with non-surgical care or compare the cost of sur-
gery with procedure reimbursement values. Further
work is therefore needed to develop more simplified rec-
ommendations for the use of micro-costing in surgery
generally and specifically for efficient and effective use of
the methodology in surgical trials. Recommendations
based on the findings of this review are summarised in
Table 5.
This is, to our knowledge, the first study to systematic-
ally identify and critically-appraise the use of micro-
costing as a method of resource-use assessment in
surgery. We used published search strategies for micro-
costing [6, 7], however due to the lack of standardisation
in micro-costing terminology and excluding non-English
language papers, our search may have overlooked other
relevant studies. The review was restricted to studies
meeting our prespecified definition of being a ‘suffi-
ciently-detailed micro-costing exercise’. This led to the
exclusion of a large number of studies at the full-text
screening stage. Inclusion of these studies would not
have been informative, but it is important to note that
costing studies in surgery more generally may be meth-
odologically less robust than those included in this re-
view. The majority of included studies scored highly on
the CHEC checklist despite an objective lack of meth-
odological rigor. This highlights the need for specific
Table 3 Reporting of micro-costing methodology
n (%)
Identified as authors as being a micro-costing study?
Yes 46 (54.1)
No 39 (45.9)
If no, authors’ description of their methodology (n = 39)
Activity-based costing or time driven activity-based
costing
27 (69.2)
Bottom up approach 4 (10.3)
Direct/detailed cost calculation 3 (7.7)
Unit costs 2 (5.1)
Cost analysis 1 (2.6)
Other/Unclear 2 (5.1)
Stated aim of the microcosting studya
To compare procedures/techniques/processes 43 (50.6)
To determine accurate costs/identify cost drivers 29 (34.1)
To compare costing methodologies (e.g. micro-costing
and HRGs)
20 (23.5)
Other stated 2 (2.3)
What aspects of the patient pathway were micro-costed
Pre-operative planning/investigations 48 (56.5)
Surgical procedure 85 (100.0)
Hospital stay 72 (84.7)
Complications of surgery 29 (34.1)
Follow up 29 (34.1)
Rehabilitation (physiotherapy/occupational therapy) 6 (7.1)
Other 1 (1.2)
Separate reporting of input utilisation and unit cost data
Yes 50 (58.8)
No 35 (41.2)
Did the authors report both direct and indirect costs
Direct costs only 24 (28.2)
Both direct and indirect costs 29 (34.1)
Not stated 32 (37.6)
Methods by which resources were identifiedb
Patient pathway mapping 32 (37.6)
Interviews with surgeons/patients 26 (30.5)
Accounting/finance department 17 (20)
Hospital information systems/administrative
databases
37 (43.5)
Direct observation 20 (23.5)
Review of patient notes/charts 16 (18.8)
Review of operating logs/books 5 (5.9)
Standardised reporting template 2 (2.3)
Manufacturer 2 (2.3)
Case report forms 1 (1.2)
Other 11 (12.9)
Table 3 Reporting of micro-costing methodology (Continued)
n (%)
Resources identified and reportedc
Personnel costs 76 (89.4)
Materials/disposables 76 (89.4)
Medical device costs 34 (40.0)
Re-usable instrument costs 16 (18.8)
Operating room costs (separate from admission
costs)
62 (72.9)
Inpatient hospital stay costs 52 (61.1)
Overhead/administration costs 46 (54.1)
Medicinal/Drug costs 63 (74.1)
Imaging/investigation/blood tests costs 39 (45.8)
Complications 5 (5.8)
Outpatient/Follow up 9 (10.5)
Perioperative care (pre-operative care/recovery) 4 (4.7)
Other costs 10 (11.7)
Did the authors identify cost drivers
Yes 72 (84.7)
No 13 (15.3)
HRG healthcare resource groups
aSome studies had more than one stated micro-costing aim
bMost studies report more than one method
cMost studies report more than one resource
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recommendations for the design, conduct and critical
appraisal of micro-costing studies to improve the quality
and value of this work.
Micro-costing produces an accurate assessment of
resource-use but the methodology is time consuming and
resource intensive and universal application alongside surgi-
cal trials would not be practical [3, 21]. A more targeted or
hybrid micro-costing approach, however, may have value
[22]. Almost all studies included in the review identified one
or more ‘cost-drivers’ that represented the greatest propor-
tion of the costs for their procedures. These differed accord-
ing to the aspects of the patient pathway considered as for
example, operating room costs were the main cost-driver in
studies just costing the surgical procedure but were less im-
portant in studies costing the full episode of care. Cost-
drivers may also be influenced by other factors such as the
specific research question and the intervention under study.
For example, a study comparing the cost of two surgical pro-
cedures identical except for the implant used might reason-
ably focus on implant cost and detailed observations of
surgeon time spent inserting the implant. Focusing attention
on identifying and accurately costing these key elements of
care while applying less detailed methods (e.g. record review
or expert opinion) for other components may allow the ben-
efits of micro-costing to be realized in an efficient way.
Process mapping with experts including surgeons, nurses,
other allied healthcare professionals and if appropriate, pa-
tients themselves may be an effective way to identify key cost
elements. More targeted, efficient micro-costing of key cost-
drivers may also allow this methodology to be applied over a
wider number of centres in a trial setting improving both the
accuracy of the costing data obtained and the generalizability
of the results [23]. Further work, however, is needed to deter-
mine if this targeted approach would be feasible alongside a
surgical trial.
As health systems and technologies become more ad-
vanced, routinely-available data may have increasing util-
ity for resource-use assessment and may make future
large-scale micro-costing studies possible. Healthcare
provider cost-accounting systems that capture details on
all resources used in an episode of care combined with
electronic theatre systems that could provide proxy time
and motion data may represent a time and cost-efficient
method for detailed resource-use assessment. Such sys-
tems and methodology, however, would need to be con-
sistent across centres if the costs generated were to be
comparable. This may be challenging, especially across
different healthcare settings and geographical locations.
Micro-costing has the potential to improve the accur-
acy of economic analyses of surgical interventions by
providing more accurate assessments of resource-use
but the overall quality of existing studies is poor. There
is a need to improve the consistency and efficiency of
micro-costing in surgery if the potential value of the
methodology is to be realised. This review highlights a
number of ways in which this could be achieved. Using
standardised terminology for micro-costing studies; fo-
cusing on identifying and accurately costing cost-drivers
relevant to the specific research question and
Table 4 Main cost drivers identified by included studiesa
(n = 72)
Main Cost-drivers Cost drivers within
the surgical
procedure alone
(n, %)
Cost drivers within
the full episode
of care
(n, %)
Operating room/theatre
cost (surgery cost/operating
room time)
17 (28.3) 0 (0.0)
Personnel/labour costs 15 (25.0) 14 (20.0)
Operative equipment
(disposable and non-
disposable, including robots)
9 (15.0) 0 (0.0)
Implant/device used in
procedure
7 (11.7) 0 (0.0)
Consumables 6 (10.0) 6 (8.6)
Medications (including blood) 4 (6.6) 5 (7.0)
Inpatient stay NA 25 (35.7)
Intensive care NA 7 (10.0)
Physiotherapy and
rehabilitation
NA 3 (4.3)
Overheads 0 (0.0) 6 (8.6)
Complications 2 (3.3) 0
Pre-operative visits NA 1 (1.4)
Medical aids NA 1 (1.4)
Imaging and diagnostic tests NA 1 (1.4)
Other 0 (0.0) 1 (1.4)
aMain cost drivers reported by authors. Other cost driver were identified but
these were stated as the ‘main’ or most important ones
Table 5 Recommendations for the efficient use of micro-
costing as a method of resource-use assessment in surgery
Key Recommendations
1. Consistently use the term ‘micro-costing’ when describing the
methodology and include ‘micro-costing’ in the abstract and as a
keyword to facilitate future identification of studies
2. Identify the potential key cost-drivers (see Table 4) for the surgical
intervention based on the research question. Patient pathway map-
ping with experts (e.g. surgeons and other healthcare professionals)
may help identify key resources.
3. For comparative cost analyses, more accurate albeit time
consuming methods (e.g observation) are warranted for resources
that differ between comparator procedures, whereas cruder
methods (e.g expert opinion) may be sufficient for inexpensive
resources with similar use between procedures.
4. Ensure transparent reporting of micro-costing studies with sufficient
disaggregation of elements of the procedure/pathway and report-
ing of unit costs (in supplementary material if necessary)
5. Consider applying focused cost-driver micro-costing at multiple
centres to improve generalisability of the results
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transparently reporting disaggregated costs for each in-
cluded resource may represent a simple strategy for im-
proving the design and delivery of future studies.
Conclusions
Micro-costing may provide a more accurate method of
resource-use assessment in economic analyses of surgi-
cal interventions and could improve the value of eco-
nomic evaluations conducted alongside surgical trials,
but this systematic review suggests that current use of
micro-costing in surgery is inconsistent and lacking in
methodological rigor. Using standardised terminology
for micro-costing studies; focusing on identifying and
accurately costing cost-drivers relevant to the specific re-
search question and transparently reporting disaggre-
gated costs for each included resource may represent a
simple strategy for the optimal design and delivery of fu-
ture studies.
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